Guardant Health Inc. (GH)

64.18
NASDAQ : Health Services
Prev Close 61.56
Day Low/High 61.12 / 65.55
52 Wk Low/High 31.01 / 112.22
Avg Volume 1.22M
Exchange NASDAQ
Shares Outstanding 92.97M
Market Cap 5.72B
EPS -2.80
P/E Ratio N/A
Div & Yield N.A. (N.A)
Data Presented At ESMO Show Metastatic CRC Patients With HER2 Amplification Detected By Guardant360 Experience Clinical Benefit After Targeted Therapy

Data Presented At ESMO Show Metastatic CRC Patients With HER2 Amplification Detected By Guardant360 Experience Clinical Benefit After Targeted Therapy

Supports Recent Addition of HER2 Blockade Therapy to NCCN Guidelines for Treatment Refractory mCRC Patients

A Tobacco Behemoth, a Craft Brewer and Other Stocks That Look Good Short

MO, VRNT and BREW all recently were downgraded by TheStreet's Quant Ratings; we also look at GH and MTCH.

Yes, the Market Hates Uncertainty

Yes, the Market Hates Uncertainty

If the macro issues calm down there should be some good trade opportunities.

A Weak Bounce Continues as Stock Picking Heats Up

A Weak Bounce Continues as Stock Picking Heats Up

The market action is creating some mis-pricing in individual stocks. But if the market stays under pressure then stock picking will remain difficult.

Guardant Health Reports Second Quarter 2019 Financial Results And Raises 2019 Revenue Guidance

Guardant Health Reports Second Quarter 2019 Financial Results And Raises 2019 Revenue Guidance

Q2 2019 revenue increase of 178% over prior year period

Largest Study Of Its Kind Finds Guardant360 MSI Highly Concordant To Tissue

Largest Study Of Its Kind Finds Guardant360 MSI Highly Concordant To Tissue

REDWOOD CITY, Calif., Aug.

Guardant Health To Participate In Upcoming Investor Conferences

Guardant Health To Participate In Upcoming Investor Conferences

REDWOOD CITY, Calif., Aug.

Stay on Guardant: GH May Hit All-Time High

Stay on Guardant: GH May Hit All-Time High

GH investors could risk a trade under $83 while probing the long side with price targets of $105 and $112.

Big Victory for the Bulls: Cramer's 'Mad Money' Recap (Monday 7/22/19)

Big Victory for the Bulls: Cramer's 'Mad Money' Recap (Monday 7/22/19)

Jim Cramer says that in the heart of earnings season, Wall Street analysts can make important calls that let bulls push stocks higher.

Berkshire Hathaway, Seattle Genetics, Zynerba: 'Mad Money' Lightning Round

Berkshire Hathaway, Seattle Genetics, Zynerba: 'Mad Money' Lightning Round

Jim Cramer takes a look at Berkshire Hathaway, Seattle Genetics, Zynerba Pharmaceuticals, Range Resources, Guardant Health, Danaher and more.

IBM, Kimberly-Clark, Alibaba: 'Mad Money' Lightning Round

IBM, Kimberly-Clark, Alibaba: 'Mad Money' Lightning Round

Jim Cramer takes a look at IBM, Kimberly-Clark, Alibaba, Guardant Health, Chesapeake Energy, Chipotle Mexican Grill, HCA Healthcare, Lumentum Holdings.

Stocks Get Chilled: Cramer's 'Mad Money' Recap (Tuesday 3/19/19)

Stocks Get Chilled: Cramer's 'Mad Money' Recap (Tuesday 3/19/19)

Jim Cramer says there's a lot to like about this market, but he says we can't ignore that it's prone to trade-related woes.

Guardant Health Posts Healthy Post-Earnings Gains

Guardant Health Posts Healthy Post-Earnings Gains

Shares in the cancer-testing services provider jump on a narrower-than-expected fiscal fourth-quarter loss.

5 Attractive Ways to Invest in Oncology

5 Attractive Ways to Invest in Oncology

Experts offer their top stock ideas in oncology detection and treatment.

Hot Cancer Detection Stock Still Has Room to Run

Hot Cancer Detection Stock Still Has Room to Run

Guardant's liquid biopsy lets oncologists see all of the genomic information of a patient's tumor with a simple blood test. The alternative is a tissue biopsy which can be expensive and risky.